In the current study, the authors specifically attempted to emulate the PRONOUNCE trial, which randomly assigned men with prostate cancer and atherosclerotic cardiovascular disease to 12 months of the gonadotropin-releasing hormone (GnRH) antagonist degarelix vs the GnRH agonist leuprolide with a primary endpoint of time to first MACE (5). Here, GNRH1 is linked to prostate cancer.